media – Page 670 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Ddu Completes Series Pre-A of Financing

Recently, Terry Yuan, the founder and CEO of Ddu, revealed that Ddu (www.drugdu.com) has raised 10 million yuan in Series Pre-A round of financing, which will be used to improve the service and build a strong team. Ddu is a global leading pharmaceuticals and medical devices online B2B platform.
- Source: Ddu
- 1,053
- May 25, 2017
Ddu News financing medical device pharmaceutical Series
Current Situation and Development Trends of China’s Rehabilitation Consumables Market

With the improvement of living standards and the enhancement of health consciousness, people’s investment in healthcare has been increased. In recent years, the scale of China's rehabilitation consumables market has been increased year by year.
- Source: Ddu
- 710
- May 23, 2017
Market Reports rehabilitation consumables
Ddu’s successful synchronization service in Hospitalar & CMEF

Both the Shanghai CMEF 2017 and Sao Paulo Hospitalar 2017 came to an end recently. As a global leading pharmaceutical and medical device B2B online platform, Ddu attended the two fairs, showcasing products of high priority users.
- Source: Ddu
- 715
- May 20, 2017
CMEF Exhibitions & Activities Hospitalar
Could Drugdu.com (Ddu) be the next unicorn after Didi and Baidu in 2017？

In which industry is the next unicorn company most likely to be born into? With the arrival of an aging society, medical trade is regarded as the industry with the most potential to produce a unicorn company.
- Source: Ddu
- 1,178
- May 20, 2017
Ddu News innovation traditional
Aspen Pharmacare hit by EU antitrust cancer drug price probe

Aspen Pharmacare is under investigation by the European Commission over its pricing practices for five cancer medicines.
- Source: pharmatimes
- 611
- May 16, 2017
cancer Company Insight EU
One in three RA patients rejecting meds because of cost

One in three people with rheumatoid arthritis in England are not taking their medicine as prescribed because of cost, according to The National Rheumatoid Arthritis Society (NRAS).
- Source: pharmatimes
- 541
- May 14, 2017
Market Views NRAS PPC
Second US approval for Merck, Pfizer’s Bavencio

Merck and Pfizer have announced a second accelerated approval in the US for Bavencio in less than two months, in this instance for certain patients with metastatic urothelial carcinoma.
- Source: pharmatimes
- 608
- May 10, 2017
cancer clinic Company Insight FDA gentic
Second US approval for Merck, Pfizer’s Bavencio

Merck and Pfizer have announced a second accelerated approval in the US for Bavencio in less than two months, in this instance for certain patients with metastatic urothelial carcinoma.
- Source: pharmatimes
- 593
- May 10, 2017
antibody Bavencio cancer New Approvals
Ddu is ready for the United O2O Exhibitions

Drugdu Technology Co., Ltd., a developer of the leading global pharmaceutical and medical device B2B platform Drugdu.com (Ddu), today announced that it will attend Hospitalar 2017 from May 16 to 19 in Sao Paulo, Brazil. Drugdu.com will showcase products of premium members and deliver innovative solutions, which are attractive not only for its users, but for the whole healthcare industry.
- Source: Ddu
- 660
- May 9, 2017
Exhibitions & Activities Hospitalar medical device sourcing request
GSK’s inhaler improves asthma control in ‘real world’ study

GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard therapy.
- Source: pharmatimes
- 594
- May 8, 2017
asthma Company Insight therapy

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.